Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan for Proliferative Vitreoretinopathy in Retinal Detachment
NCT05523869Phase 2Recruiting
- Sponsor
- Unity Health Toronto
- Start
- Feb 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of topotecan in Proliferative Vitreoretinopathy (PVR), sponsored by Unity Health Toronto. Started Feb 2023; status: recruiting.
02
Drugs
topotecan
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT05523869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523869.